Fenotipos de linfocitos periféricos en las enfermedades de Alzheimer y Parkinson

Dorsey, 2007, Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030, Neurology, 68, 384, 10.1212/01.wnl.0000247740.47667.03 Hebert, 2013, Alzheimer disease in the United States (2010-2050) estimated using the 2010 census, Neurology, 80, 1778, 10.1212/WNL.0b013e31828726f5 Collier, 2011, Ageing as a primary risk factor for Parkinson's disease: Evidence from studies of non-human primates, Nat Rev Neurosci, 12, 359, 10.1038/nrn3039 Chin-Chan, 2015, Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases, Front Cell Neurosci, 9, 124, 10.3389/fncel.2015.00124 Pihlstrøm, 2017, Genetics of neurodegenerative diseases: An overview, Handb Clin Neurol, 145, 309, 10.1016/B978-0-12-802395-2.00022-5 Prince, 2013, The global prevalence of dementia: A systematic review and metaanalysis, Alzheimers Dement, 9, 63, 10.1016/j.jalz.2012.11.007 Pringsheim, 2014, The prevalence of Parkinson's disease: A systematic review and meta-analysis, Mov Disord, 29, 1583, 10.1002/mds.25945 Poewe, 2017, Parkinson disease, Nat Rev Dis Primers, 3, 17013, 10.1038/nrdp.2017.13 Lunn, 2011, Stem cell technology for neurodegenerative diseases, Ann Neurol, 70, 353, 10.1002/ana.22487 Reitz, 2011, Epidemiology of Alzheimer disease, Nat Rev Neurol, 7, 137, 10.1038/nrneurol.2011.2 Bisaglia, 2014, Are dopamine derivatives implicated in the pathogenesis of Parkinson's disease?, Ageing Res Rev, 13, 107, 10.1016/j.arr.2013.12.009 Varcin, 2012, Oxidative stress in genetic mouse models of Parkinson's disease, Oxid Med Cell Longev, 2012, 624925, 10.1155/2012/624925 Rocha, 2015, Insights into neuroinflammation in Parkinson's disease: From biomarkers to anti-inflammatory based therapies, Biomed Res Int, 2015, 628192, 10.1155/2015/628192 Mietelska-Porowska, 2017, T lymphocytes and inflammatory mediators in the interplay between brain and blood in Alzheimer's disease: Potential pools of new biomarkers, J Immunol Res, 2017, 4626540, 10.1155/2017/4626540 Appel, 2009, CD4+ T cells mediate cytotoxicity in neurodegenerative diseases, J Clin Invest, 119, 13 Bagyinszky, 2017, Role of inflammatory molecules in the Alzheimer's disease progression and diagnosis, J Neurol Sci, 376, 242, 10.1016/j.jns.2017.03.031 Arosio, 2014, Peripheral blood mononuclear cells as a laboratory to study dementia in the elderly, Biomed Res Int, 2014, 169203, 10.1155/2014/169203 Rezai-Zadeh, 2009, Can peripheral leukocytes be used as Alzheimer's disease biomarkers?, Expert Rev Neurother, 9, 1623, 10.1586/ern.09.118 Clark, 2016, The immune system and neuroinflammation as potential sources of blood-based biomarkers for Alzheimer's disease Parkinson's disease, and Huntington's disease, ACS Chem Neurosci, 7, 520, 10.1021/acschemneuro.6b00042 Esteras, 2016, Lymphocytes in Alzheimer's disease pathology: Altered signaling pathways, Curr Alzheimer Res, 13, 439, 10.2174/1567205013666151116124912 Richartz-Salzburger, 2007, Altered lymphocyte distribution in Alzheimer's disease, J Psychiatr Res, 41, 174, 10.1016/j.jpsychires.2006.01.010 Speciale, 2007, Lymphocyte subset patterns and cytokine production in Alzheimer's disease patients, Neurobiol Aging, 28, 1163, 10.1016/j.neurobiolaging.2006.05.020 Lueg, 2015, Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease, Neurobiol Aging, 36, 81, 10.1016/j.neurobiolaging.2014.08.008 Larbi, 2009, Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease, J Alzheimers Dis, 17, 91, 10.3233/JAD-2009-1015 Saunders, 2012, CD4+ regulatory and effector/memory T cell subsets profile motor dysfunction in Parkinson's disease, J Neuroimmune Pharmacol, 7, 927, 10.1007/s11481-012-9402-z Chen, 2015, Clinical correlation of peripheral CD4+-cell sub-sets, their imbalance and Parkinson's disease, Mol Med Rep, 12, 6105, 10.3892/mmr.2015.4136 McKahnn, 1984, Clinical diagnosis of Alzheimer's disease: Report of the NINCDS- ADRDA work group under the auspices of the department of health and human services task force on Alzheimer's disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 Hughes, 1992, Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases, J Neurol Neurosurg Psychiatry, 55, 181, 10.1136/jnnp.55.3.181 Goetz, 2004, movement disorder society task force report on the Hoehn and Yahr staging scale: Status and recommendations, Mov Disord, 19, 1020, 10.1002/mds.20213 Clark, 1996, Performance of the dementia severity rating scale: A caregiver questionnaire for rating severity in Alzheimer disease, Alzheimer Dis Assoc Disord, 10, 31 Muldoon, 2013, Immunologic privilege in the central nervous system and the blood-brain barrier, J Cereb Blood Flow Metab, 33, 13, 10.1038/jcbfm.2012.153 Fabry, 2008, Sensing the microenvironment of the central nervous system: Immune cells in the central nervous system and their pharmacological manipulation, Curr Opin Pharmacol, 8, 496, 10.1016/j.coph.2008.07.009 McManus, 2017, Role of neuroinflammation in neurodegeneration: new insights, Alzheimers Res Ther, 9, 14, 10.1186/s13195-017-0241-2 Selmaj, 2017, The role of exosomes in CNS inflammation and their involvement in multiple sclerosis, J Neuroimmunol, 306, 1, 10.1016/j.jneuroim.2017.02.002 Hirsch, 2012, Neuroinflammation in Parkinson's disease, Parkinsonism Relat Disord, 18, S210, 10.1016/S1353-8020(11)70065-7 More, 2013, Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease, Mediators Inflamm, 2013, 952375, 10.1155/2013/952375 Calopa, 2010, Apoptosis of peripheral blood lymphocytes in Parkinson patients, Neurobiol Dis, 38, 1, 10.1016/j.nbd.2009.12.017 Schwartz, 2014, Breaking peripheral immune tolerance to CNS antigens in neurodegenerative diseases: Boosting autoimmunity to fight-off chronic neuroinflammation, J Autoimmun, 54, 8, 10.1016/j.jaut.2014.08.002 Thornton, 1998, CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production, J Exp Med, 188, 287, 10.1084/jem.188.2.287 Duffy, 2018, The role of regulatory T cells in nervous system pathologies, J Neurosci Res, 96, 951, 10.1002/jnr.24073 Dansokho, 2016, Regulatory T cells delay disease progression in Alzheimer-like pathology, Brain, 139, 1237, 10.1093/brain/awv408 Reynolds, 2007, Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease, J Leukoc Biol, 82, 1083, 10.1189/jlb.0507296 Reynolds, 2010, Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease, J Immunol, 184, 2261, 10.4049/jimmunol.0901852 Lan, 2012, Induced Foxp3(+) regulatory T cells: A potential new weapon to treat autoimmune and inflammatory diseases?, J Mol Cell Biol, 4, 22, 10.1093/jmcb/mjr039 Lowther, 2012, Regulatory T cells in the central nervous system, Immunol Rev, 248, 156, 10.1111/j.1600-065X.2012.01130.x Baruch, 2015, Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer's disease pathology, Nat Commun, 6, 7967, 10.1038/ncomms8967 Xing, 2015, Critical role for thymic CD19+CD5+CD1dhiIL-10+ regulatory B cells in immune homeostasis, J Leukoc Biol, 97, 547, 10.1189/jlb.3A0414-213RR Wherry, 2003, Lineage relationship and protective immunity of memory CD8 T cell subsets, Nat Immunol, 4, 225, 10.1038/ni889 Reale, 2014, Selective acetyl- and butyrylcholinesterase inhibitors reduce amyloid-β ex vivo activation of peripheral chemo-cytokines from Alzheimer's disease subjects: Exploring the cholinergic anti-inflammatory pathway, Curr Alzheimer Res, 11, 608, 10.2174/1567205010666131212113218